• AMPK’s Dual Role in Autophagy: New Insights from Energy Stre

  2026-08-04

  This study challenges the prevailing paradigm by showing that AMPK suppresses, rather than activates, ULK1-mediated autophagy under energy stress. The findings have major implications for interpreting autophagy inhibition, vesicle trafficking modulation, and the use of Vps34 inhibitors in metabolic and cancer research.

• ETS1 Modulates SUMOylation-Dependent Mitophagy in BPD Models

  2026-08-04

  The reference study uncovers a novel mechanism by which the transcription factor ETS1 alleviates bronchopulmonary dysplasia (BPD) through regulation of the SENP2/HSPA8/FUNDC1 axis and inhibition of SUMOylation-dependent mitophagy. These findings highlight a new molecular target for therapeutic intervention in neonatal lung injury, with implications for translational research on posttranslational modification inhibitors.

• HyperScribe™ T7 High Yield RNA Synthesis Kit: Advancing RNA

  2026-08-03

  Explore how the HyperScribe T7 High Yield RNA Synthesis Kit enables precise, high-yield in vitro RNA synthesis for advanced research, including applications in disease modeling and therapeutic development. This article uniquely bridges technical assay optimization with emerging biomaterial-based repair strategies.

• Mdivi-1: Selective DRP1 Inhibitor for Mitochondrial Dynamics

  2026-08-03

  Mdivi-1, a selective DRP1 inhibitor from APExBIO, empowers researchers to precisely dissect mitochondrial fission, apoptosis, and neuroprotection in both cell-based and in vivo models. This guide integrates the latest evidence and protocols to streamline workflows, troubleshoot common pitfalls, and maximize data fidelity in mitochondrial dynamics research.

• Fucoidan-Induced Caveolin-1 Downregulation in MCF-7 Cells

  2026-08-02

  This study reveals that fucoidan, a sulfated polysaccharide from brown algae, selectively reduces caveolin-1 expression in MCF-7 breast cancer cells, highlighting a novel antitumor mechanism. The findings suggest new directions for targeted therapies, with implications for enhancing current breast cancer research models.

• Protease and Phosphatase Inhibitor Cocktail (EDTA Free, 100X

  2026-08-01

  The Protease and Phosphatase Inhibitor Cocktail (EDTA Free, 100X in ddH2O) addresses protein degradation and dephosphorylation during extraction and lysis, particularly when preservation of native phosphorylation states is required. This product is suitable for workflows that cannot tolerate EDTA, including those involving metal-dependent enzymes or downstream metal-affinity purification. It should not be used where EDTA-mediated inhibition is necessary or where long-term sample storage without immediate processing is planned.

• Imeglimin Enhances Mitochondrial Function in CTS-Related SSC

  2026-07-31

  The reference study demonstrates that Imeglimin significantly improves mitochondrial function and reduces apoptosis in subsynovial connective tissue (SSCT) cells derived from patients with idiopathic carpal tunnel syndrome (CTS). These findings offer new mechanistic insights into mitochondrial dysfunction in CTS and suggest practical directions for future research and potential therapeutic intervention.

• β-Blocker Selectivity and Hematopoietic Regeneration Post-Tr

  2026-07-31

  This study reveals that nonselective β-adrenergic blockers, but not β1-selective agents, significantly impair hematopoietic regeneration after hematopoietic cell transplantation (HCT) in both mice and humans. The findings have direct implications for cardiovascular and hematopoietic research design, highlighting the importance of β1-adrenergic receptor selectivity in experimental and clinical protocols.

• PDK4-IN-1 Hydrochloride: Precision Targeting of Mitochondria

  2026-07-30

  Explore how PDK4-IN-1 hydrochloride, a potent pyruvate dehydrogenase kinase 4 inhibitor, enables advanced modulation of mitochondrial energy metabolism. This article uniquely dissects its mechanistic foundation, translational impact, and assay design for metabolic and disease research.

• Trichostatin A (TSA): Advanced Epigenetic Workflow Optimizat

  2026-07-30

  Trichostatin A (TSA) is a benchmark HDAC inhibitor for dissecting epigenetic regulation and cell fate decisions in cancer and organoid models. This guide delivers actionable protocols, troubleshooting, and translational strategies to maximize TSA’s precision and reproducibility in high-throughput and differentiation-focused research.

• Bafilomycin A1: Unraveling V-ATPase Inhibition in Redox and

  2026-07-29

  Explore how Bafilomycin A1, a potent V-ATPase inhibitor, empowers advanced research on intracellular pH, redox balance, and autophagy. This article delivers fresh insight into assay design and translational impact, extending beyond standard protocol reviews.

• β-Blocker Selectivity Shapes Hematopoietic Regeneration Post

  2026-07-29

  This study demonstrates that nonselective β-adrenergic blockers, but not β1-selective agents, impair hematopoietic regeneration following hematopoietic cell transplantation (HCT) in both mice and humans. The findings challenge assumptions about β-blocker safety in post-HCT care and offer important guidance for the selection of cardiovascular therapies in hematopoietic and regenerative research.

• Advances in Plant Protein Secretion Protocols: Insights and

  2026-07-28

  The second edition of 'Plant Protein Secretion: Methods and Protocols' delivers rigorously detailed, stepwise protocols for dissecting both conventional and unconventional protein secretion in plant cells. This resource clarifies plant-specific secretory mechanisms, providing technical depth and reproducibility that directly supports experimental innovation in plant biology.

• MAPK10 Regulates KRT16 Ubiquitination to Suppress NSCLC Meta

  2026-07-28

  This study uncovers a phosphorylation-dependent mechanism by which MAPK10 inhibits non-small cell lung cancer metastasis through the ubiquitination and degradation of keratin 16. The findings clarify the prognostic value of the MAPK10/KRT16/RNF213 axis and suggest new directions for targeted therapies.

• Atorvastatin in Translational Ferroptosis and Vascular Resea

  2026-07-27

  Explore how Atorvastatin redefines HMG-CoA reductase inhibitor research, bridging cholesterol metabolism, vascular cell biology, and ferroptosis-driven oncology. This article offers advanced protocol guidance and deep analysis of recent innovations in cardiovascular and cancer biology.

16261 records 1/1085 page Next 12345 下5页 Last page